Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Kerr

Showing results (211-220 of 221) with videos related to

Pageof 23
Sort By:
Blood|July 9, 1999
Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's diseaseP G Murray, L J Billingham, H T Hassan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanR S Midgley, D J Kerr, K T Flaherty, et al.
Oncogene|November 21, 1996
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediatorA G Eliopoulos, C W Dawson, G Mosialos, et al.
Cancer Gene Therapy|July 1, 1997
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase geneN K Green, D J Youngs, J P Neoptolemos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancerD W Rea, J W R Nortier, W W Ten Bokkel Huinink, et al.
Lancet (London, England)|November 22, 2001
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trialJ P Neoptolemos, J A Dunn, D D Stocken, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
Prognostic markers for colorectal cancer: estimating ploidy and stromaH E Danielsen, T S Hveem, E Domingo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trialA Huijbers, R A E M Tollenaar, G W v Pelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research CouncilM T Seymour, M L Slevin, D J Kerr, et al.
Annals of Surgery|December 1, 2001
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trialJ P Neoptolemos, D D Stocken, J A Dunn, et al.
Pageof 23

Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
Blood|July 9, 1999
Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's diseaseP G Murray, L J Billingham, H T Hassan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanR S Midgley, D J Kerr, K T Flaherty, et al.
Oncogene|November 21, 1996
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediatorA G Eliopoulos, C W Dawson, G Mosialos, et al.
Cancer Gene Therapy|July 1, 1997
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase geneN K Green, D J Youngs, J P Neoptolemos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancerD W Rea, J W R Nortier, W W Ten Bokkel Huinink, et al.
Lancet (London, England)|November 22, 2001
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trialJ P Neoptolemos, J A Dunn, D D Stocken, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
Prognostic markers for colorectal cancer: estimating ploidy and stromaH E Danielsen, T S Hveem, E Domingo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trialA Huijbers, R A E M Tollenaar, G W v Pelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research CouncilM T Seymour, M L Slevin, D J Kerr, et al.
Annals of Surgery|December 1, 2001
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trialJ P Neoptolemos, D D Stocken, J A Dunn, et al.
Pageof 23